Minimally invasivE versus open total GAstrectomy (MEGA): study protocol for a multicentre randomised controlled trial (DRKS00025765). Issue 10 (31st October 2022)

• Record Type: Journal Article
• Authors: Nickel, Felix; Studier-Fischer, Alexander; Hausmann, David; Klotz, Rosa; Vogel-Adigozalov, Sophia Lara; Tenckhoff, Solveig; Klose, Christina; Feisst, Manuel; Zimmermann, Samuel; Babic, Benjamin; Berlt, Felix; Bruns, Christiane; Gockel, Ines; Graf, Sandra; Grimminger, Peter; Gutschow, Christian A; Hoeppner, Jens; Ludwig, Kaja; Mirow, Lutz; Mönig, Stefan; Reim, Daniel; Seyfried, Florian; Stange, Daniel; Billeter, Adrian; Nienhüser, Henrik; Probst, Pascal; Schmidt, Thomas; Müller-Stich, Beat Peter
• Is Part Of: BMJ open. Volume 12:Issue 10(2022)
• Publication Date: 2022-10-31
• Subjects: surgery -- oncology -- gastrointestinal tumours; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2022-064286
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: The only curative treatment for most gastric cancer is radical gastrectomy with D2 lymphadenectomy (LAD). Minimally invasive total gastrectomy (MIG) aims to reduce postoperative morbidity, but its use has not yet been widely established in Western countries. Minimally invasivE versus open total GAstrectomy is the first Western multicentre randomised controlled trial (RCT) to compare postoperative morbidity following MIG vs open total gastrectomy (OG). Methods and analysis: This superiority multicentre RCT compares MIG (intervention) to OG (control) for oncological total gastrectomy with D2 or D2+LAD. Recruitment is expected to last for 2 years. Inclusion criteria comprise age between 18 and 84 years and planned total gastrectomy after initial diagnosis of gastric carcinoma. Exclusion criteria include Eastern Co-operative Oncology Group (ECOG) performance status >2, tumours requiring extended gastrectomy or less than total gastrectomy, previous abdominal surgery or extensive adhesions seriously complicating MIG, other active oncological disease, advanced stages (T4 or M1), emergency setting and pregnancy. The sample size was calculated at 80 participants per group. The primary endpoint is 30-day postoperative morbidity as measured by the Comprehensive Complications Index. Secondary endpoints include postoperative morbidity and mortality, adherence to a fast-track protocol and patient-reported quality of life (QoL) scores (QoR-15, EUROQOL EuroQol-5 Dimensions-5 Levels (EQ-5D), EORTC QLQ-C30, EORTC QLQ-STO22, activities of daily living and Body Image Scale). Oncological endpoints include rate of R0 resection, lymph node yield, disease-free survival and overall survival at 60-month follow-up. Ethics and dissemination: Ethical approval has been received by the independent Ethics Committee of the Medical Faculty, University of Heidelberg (S-816/2021) and will be received from each responsible ethics committee for each individual participating centre prior to recruitment. Results will be published open access. Trial registration number: DRKS00025765.